XIMLUCI
As listed in the register: XIMLUCI 10 mg/mL, solution injectable
10 mg · solution injectable
- Prescription only
- Active substance
- Ranibizumab
- Made by
- STADA ARZNEIMITTEL AG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (LUCENTIS). It describes the substance, not this exact product.
Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF 110.
VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and is thought to contribute to pathophysiology of neovascular AMD, mCNV, DR, DME and macular edema following RVO.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-11-21
Safety of the active substance
From the US prescribing label for the same active substance (LUCENTIS). It describes the substance, not this exact product.
- Ocular or periocular infections ( 4.1 ) Hypersensitivity ( 4.2 ) 4.1 Ocular or Periocular Infections LUCENTIS is contraindicated in patients with ocular or periocular infections. 4.2 Hypersensitivity LUCENTIS is contraindicated in patients with known hypersensitivity to ranibizumab or any of the excipients in LUCENTIS.
- Hypersensitivity reactions may manifest as severe intraocular inflammation.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Spain14 matching products
- LUCENTIS 10 MG/ML · solución inyectable3 makers
- BYOOVIZ 10 MG/ML · solución inyectable2 makers
- RANIVISIO 10 MG/ML · solución inyectable2 makers
- RANLUSPEC 10 mg/ml · solución inyectable2 makers
- REXATILUX 10 mg/ml · solución inyectable2 makers
- RIMMYRAH 10 mg/ml · solución inyectable2 makers
- XIMLUCI 10 MG/ML · solución inyectable
CanadaNo exact match for this strength and form
Netherlands11 matching products
- Byooviz 10 mg/ml 10 mg/ml · oplossing voor injectie
- Epruvy 10 mg/ml oplossing voor injectie 10 mg/ml · oplossing voor injectie
- LUCENTIS 10 MG/ML 10 MG/ML · oplossing voor injectie
- Ranivisio 10 mg/ml 10 mg/ml · oplossing voor injectie
- Ranluspec 10 mg/ml oplossing voor injectie 10 mg/ml · oplossing voor injectie
- Ranluspec 10 mg/ml oplossing voor injectie in een voorgevulde spuit 10 mg/ml · oplossing voor injectie
- Rexatilux 10 mg/ml oplossing voor injectie 10 mg/ml · oplossing voor injectie
- Rimmyrah 10 mg/ml 10 mg/ml · oplossing voor injectie
Details
| Made by | STADA ARZNEIMITTEL AG |
|---|---|
| Active substance | Ranibizumab |
| Strength | 10 mg |
| Form | solution injectable |
| Route | intravitréenne |
| Dispensing (as stated by the register) | prescription réservée aux spécialistes et services OPHTALMOLOGIE · liste I |
| Marketed | Yes, according to the register |
| Reinforced monitoring | Yes — under reinforced monitoring, according to the register |
| Authorisation procedure | Procédure centralisée |
| EU number | EU/1/22/1691 |
| Name in the register | XIMLUCI 10 mg/mL, solution injectable |
| Packs | 1 flacon(s) en verre de 0,23 ml avec aiguille(s) filtre(s) |
| CIS | 67026689 |
| CIP13 | 3400930266922 |
Source: Base de données publique des médicaments · 2026-09-30 · not reviewed by a clinician
Source : Base de données publique des médicaments (ANSM / Ministère de la Santé), sous Licence Ouverte. Reuse terms: Licence Ouverte / Open Licence (Etalab).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.